MX387775B - Derivado de 2-acilaminotiazol o sal del mismo. - Google Patents
Derivado de 2-acilaminotiazol o sal del mismo.Info
- Publication number
- MX387775B MX387775B MX2019014490A MX2019014490A MX387775B MX 387775 B MX387775 B MX 387775B MX 2019014490 A MX2019014490 A MX 2019014490A MX 2019014490 A MX2019014490 A MX 2019014490A MX 387775 B MX387775 B MX 387775B
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- bladder
- urinary
- muscarinic
- treatment
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 2
- 210000003932 urinary bladder Anatomy 0.000 abstract 4
- 208000012931 Urologic disease Diseases 0.000 abstract 3
- 230000003551 muscarinic effect Effects 0.000 abstract 3
- 208000014001 urinary system disease Diseases 0.000 abstract 3
- 230000008602 contraction Effects 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 208000026533 urinary bladder disease Diseases 0.000 abstract 2
- 208000004168 Underactive Urinary Bladder Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010013990 dysuria Diseases 0.000 abstract 1
- 239000008196 pharmacological composition Substances 0.000 abstract 1
- -1 pyrazinylcarbonylamino Chemical group 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 150000007979 thiazole derivatives Chemical group 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Se proporciona un compuesto el cual es útil como un ingrediente activo para una composición farmacéutica para prevenir o tratar la disfunción en el almacenamiento de orina, disfunción en la evacuación, disfunción del tracto urinario inferior y similares. Los presentes inventores han descubierto que un derivado de tiazol sustituido con pirazinilcarbonilamino en la posición 2 es un excelente modulador alostérico positivo del receptor muscarínico M3 y se pronostica como un agente para prevenir o tratar enfermedades de la vejiga / tracto urinario asociadas con las contracciones de la vejiga por un receptor M3 muscarínico, completando así la presente invención. El derivado de 2-acilaminotiazol o una sal del mismo de la presente invención se espera que tenga utilidad como un agente para prevenir o tratar enfermedades de la vejiga/tracto urinario asociadas con las contracciones de la vejiga por un receptor M3 muscarínico, por ejemplo disfunción en la evacuación tal como vejiga hipoactiva y similares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014118046 | 2014-06-06 | ||
| PCT/JP2015/066321 WO2015186821A1 (ja) | 2014-06-06 | 2015-06-05 | ２－アシルアミノチアゾール誘導体またはその塩 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX387775B true MX387775B (es) | 2025-03-18 |
Family
ID=54766887
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014490A MX387775B (es) | 2014-06-06 | 2015-06-05 | Derivado de 2-acilaminotiazol o sal del mismo. |
| MX2016016134A MX370140B (es) | 2014-06-06 | 2015-06-05 | Derivado de 2-acilaminotiazol o sal del mismo. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016016134A MX370140B (es) | 2014-06-06 | 2015-06-05 | Derivado de 2-acilaminotiazol o sal del mismo. |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | USRE49111E1 (es) |
| EP (1) | EP3153511B1 (es) |
| JP (1) | JP6319436B2 (es) |
| KR (1) | KR102482844B1 (es) |
| CN (2) | CN110845490B (es) |
| AR (1) | AR100748A1 (es) |
| AU (1) | AU2015269449B2 (es) |
| BR (1) | BR112016028270B1 (es) |
| CA (1) | CA2950564C (es) |
| CO (1) | CO2017000044A2 (es) |
| CY (1) | CY1122290T1 (es) |
| DK (1) | DK3153511T3 (es) |
| EA (1) | EA031866B1 (es) |
| ES (1) | ES2732066T3 (es) |
| HR (1) | HRP20190943T1 (es) |
| HU (1) | HUE043496T2 (es) |
| IL (1) | IL249356B (es) |
| LT (1) | LT3153511T (es) |
| MA (1) | MA39950B1 (es) |
| ME (1) | ME03438B (es) |
| MX (2) | MX387775B (es) |
| MY (1) | MY197712A (es) |
| NZ (1) | NZ727142A (es) |
| PH (1) | PH12016502405B1 (es) |
| PL (1) | PL3153511T3 (es) |
| PT (1) | PT3153511T (es) |
| RS (1) | RS58809B1 (es) |
| SA (1) | SA516380427B1 (es) |
| SG (2) | SG10202000463YA (es) |
| SI (1) | SI3153511T1 (es) |
| SM (1) | SMT201900352T1 (es) |
| TR (1) | TR201908676T4 (es) |
| TW (2) | TWI745877B (es) |
| UA (1) | UA122208C2 (es) |
| WO (1) | WO2015186821A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008079112A1 (en) | 2006-12-20 | 2008-07-03 | Thomson Licensing | Embedded audio routing switcher |
| TR201908031T4 (tr) | 2014-08-26 | 2019-06-21 | Astellas Pharma Inc | İdrar kesesi hastalıklarının tedavisine yönelik muskarinik m3 ligandları olarak 2-aminotiyazol türevleri veya bunların tuzu. |
| JP7063902B2 (ja) | 2016-12-19 | 2022-05-09 | ノバルティス アーゲー | 新たなピコリン酸誘導体及び中間体としてのその使用 |
| WO2019189766A1 (ja) * | 2018-03-30 | 2019-10-03 | 持田製薬株式会社 | 新規ビアリールアミド誘導体 |
| ES2992256T3 (es) | 2018-05-08 | 2024-12-11 | Nippon Shinyaku Co Ltd | Compuestos de azabencimidazol y producto farmacéutico |
| CN111718293A (zh) * | 2019-03-18 | 2020-09-29 | 持田制药株式会社 | 双芳基酰胺衍生物的制造方法 |
| EP3967311A1 (en) * | 2020-09-11 | 2022-03-16 | Astellas Pharma Inc. | Compounds for use in the treatment of dry mouth |
| EP4631506A1 (en) | 2022-12-09 | 2025-10-15 | Asahi Pharma Co., Ltd. | Body fluid regulating agent, combination agent for body fluid regulation and use of compound |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA73543C2 (uk) | 1999-12-07 | 2005-08-15 | Тераванс, Інк. | Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором |
| JP2001278872A (ja) * | 2000-03-27 | 2001-10-10 | Banyu Pharmaceut Co Ltd | 新規アミノチアゾール誘導体 |
| EP1289965B1 (en) * | 2000-05-25 | 2005-10-26 | F. Hoffmann-La Roche Ag | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists |
| US20050014942A1 (en) * | 2001-10-30 | 2005-01-20 | Yasufumi Maruyama | Amide derivatives and drugs |
| KR101010905B1 (ko) | 2002-01-18 | 2011-01-25 | 아스텔라스세이야쿠 가부시키가이샤 | 2-아실아미노티아졸 유도체 또는 그 염 |
| TWI242478B (en) | 2002-08-01 | 2005-11-01 | Masami Nakamoto | Metal nanoparticle and process for producing the same |
| AR040779A1 (es) * | 2002-08-06 | 2005-04-20 | Glaxo Group Ltd | Compuesto de tiazol anilina su uso para preparar una formulacion farmaceutica dicha formulacion recipiente que la contiene y dispositivo adaptado para la administracion intranasal de la formulacion |
| CA2529686C (en) | 2003-07-17 | 2010-06-15 | Astellas Pharma Inc. | 2-acylaminothiazole derivative or salt thereof |
| JP4665769B2 (ja) | 2005-01-12 | 2011-04-06 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体の製造法 |
| JP4774995B2 (ja) * | 2005-01-12 | 2011-09-21 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体を有効成分とする医薬組成物 |
| CN101490003A (zh) * | 2006-04-24 | 2009-07-22 | 阿斯利康(瑞典)有限公司 | 具有毒蕈碱m3受体拮抗剂活性、用于治疗入慢性支气管阻塞、哮喘和膀胱过动的新型环状氨基醇的取代烷基酯类化合物 |
| US8304547B2 (en) | 2007-10-24 | 2012-11-06 | Astellas Pharma Inc. | Azolecarboxamide compound or salt thereof |
| AU2011283684B2 (en) | 2010-07-29 | 2015-08-27 | Rigel Pharmaceuticals, Inc. | AMPK-activating heterocyclic compounds and methods for using the same |
| TWI647227B (zh) * | 2013-02-28 | 2019-01-11 | 日商安斯泰來製藥股份有限公司 | ２－醯胺噻唑衍生物或其鹽 |
-
2015
- 2015-06-05 MX MX2019014490A patent/MX387775B/es unknown
- 2015-06-05 KR KR1020177000217A patent/KR102482844B1/ko active Active
- 2015-06-05 MY MYPI2016704529A patent/MY197712A/en unknown
- 2015-06-05 TW TW109106548A patent/TWI745877B/zh active
- 2015-06-05 ME MEP-2019-163A patent/ME03438B/me unknown
- 2015-06-05 LT LTEP15803484.3T patent/LT3153511T/lt unknown
- 2015-06-05 MA MA39950A patent/MA39950B1/fr unknown
- 2015-06-05 CN CN201911226515.2A patent/CN110845490B/zh active Active
- 2015-06-05 US US16/856,738 patent/USRE49111E1/en active Active
- 2015-06-05 AU AU2015269449A patent/AU2015269449B2/en active Active
- 2015-06-05 HU HUE15803484A patent/HUE043496T2/hu unknown
- 2015-06-05 SM SM20190352T patent/SMT201900352T1/it unknown
- 2015-06-05 CN CN201580030154.8A patent/CN106414438B/zh active Active
- 2015-06-05 UA UAA201700205A patent/UA122208C2/uk unknown
- 2015-06-05 HR HRP20190943TT patent/HRP20190943T1/hr unknown
- 2015-06-05 AR ARP150101792A patent/AR100748A1/es active IP Right Grant
- 2015-06-05 ES ES15803484T patent/ES2732066T3/es active Active
- 2015-06-05 TW TW104118315A patent/TWI689507B/zh active
- 2015-06-05 MX MX2016016134A patent/MX370140B/es active IP Right Grant
- 2015-06-05 PT PT15803484T patent/PT3153511T/pt unknown
- 2015-06-05 RS RS20190710A patent/RS58809B1/sr unknown
- 2015-06-05 DK DK15803484.3T patent/DK3153511T3/da active
- 2015-06-05 TR TR2019/08676T patent/TR201908676T4/tr unknown
- 2015-06-05 NZ NZ727142A patent/NZ727142A/en unknown
- 2015-06-05 SI SI201530787T patent/SI3153511T1/sl unknown
- 2015-06-05 SG SG10202000463YA patent/SG10202000463YA/en unknown
- 2015-06-05 JP JP2016525246A patent/JP6319436B2/ja active Active
- 2015-06-05 BR BR112016028270-1A patent/BR112016028270B1/pt active IP Right Grant
- 2015-06-05 EA EA201692469A patent/EA031866B1/ru not_active IP Right Cessation
- 2015-06-05 US US15/316,645 patent/US9951060B2/en not_active Ceased
- 2015-06-05 SG SG11201610201UA patent/SG11201610201UA/en unknown
- 2015-06-05 CA CA2950564A patent/CA2950564C/en active Active
- 2015-06-05 PL PL15803484T patent/PL3153511T3/pl unknown
- 2015-06-05 WO PCT/JP2015/066321 patent/WO2015186821A1/ja not_active Ceased
- 2015-06-05 EP EP15803484.3A patent/EP3153511B1/en active Active
-
2016
- 2016-12-02 PH PH12016502405A patent/PH12016502405B1/en unknown
- 2016-12-04 IL IL24935616A patent/IL249356B/en active IP Right Grant
- 2016-12-05 SA SA516380427A patent/SA516380427B1/ar unknown
-
2017
- 2017-01-04 CO CONC2017/0000044A patent/CO2017000044A2/es unknown
-
2019
- 2019-06-19 CY CY20191100631T patent/CY1122290T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX387775B (es) | Derivado de 2-acilaminotiazol o sal del mismo. | |
| MY190361A (en) | 2-acylaminothiazole derivative or salt thereof | |
| MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| PH12015502628B1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| BR112017016817A2 (pt) | derivados heterocíclicos formilados como inibidores de fgfr4 | |
| AR103680A1 (es) | Inhibidores selectivos de bace1 | |
| EA201692542A1 (ru) | Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы | |
| EA201891267A1 (ru) | Фармацевтическая композиция, содержащая действенный ингибитор urat1 | |
| EA033250B1 (ru) | Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет | |
| EA201300436A8 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| EA201591815A1 (ru) | Бицикло [2.2.2] кислоты - модуляторы gpr120 | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| EA201692298A1 (ru) | Производные карбоксамидов | |
| CY1119483T1 (el) | Θεραπευτικος παραγων για τις αγχωδεις διαταραχες | |
| EA201890684A1 (ru) | Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1 | |
| BR112015010823A2 (pt) | composto de 2-piridona | |
| MX2017002500A (es) | Derivado de 2-aminotiazol o sal del mismo. | |
| NZ764561A (en) | Substituted azacycles as muscarinic m1 receptor positive allosteric modulators | |
| AR101394A1 (es) | COMPUESTO DE 6,7-DIHIDROPIRAZOLO[1,5-A]PIRAZIN-4(5H)-ONA Y SU USO COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE RECEPTORES mGluR2 |